StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Heron Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Heron Therapeutics's total assets was $252.26M at Jun 30, 2026. For fiscal 2025 it was $255.88M, up 9.7% from the year before. Over ten years it grew 6.4% a year on average. The highest annual figure on record is $512.78M in fiscal 2019.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$255.88M+9.7%
FY2024Dec 31, 2024$233.15M+4.8%
FY2023Dec 31, 2023$222.51M-11.3%
FY2022Dec 31, 2022$250.95M-17.9%
FY2021Dec 31, 2021$305.71M-13.5%
FY2020Dec 31, 2020$353.56M-31.1%
FY2019Dec 31, 2019$512.78M+10.9%
FY2018Dec 31, 2018$462.18M+97.3%
FY2017Dec 31, 2017$234.31M+247.2%
FY2016Dec 31, 2016$67.48M-51.0%
FY2015Dec 31, 2015$137.85M+79.8%
FY2014Dec 31, 2014$76.68M+1.0%
FY2013Dec 31, 2013$75.94M+35.7%
FY2012Dec 31, 2012$55.97M+187.8%
FY2011Dec 31, 2011$19.45M+568.0%
FY2010Dec 31, 2010$2.91M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$252.26M+8.7%
Q1 FY2026Mar 31, 2026$246.22M+4.4%
Q4 FY2025Dec 31, 2025$255.88M+9.7%
Q3 FY2025Sep 30, 2025$248.95M+12.8%
Q2 FY2025Jun 30, 2025$232.09M+6.4%
Q1 FY2025Mar 31, 2025$235.75M+8.2%
Q4 FY2024Dec 31, 2024$233.15M+4.8%
Q3 FY2024Sep 30, 2024$220.78M-3.7%
Q2 FY2024Jun 30, 2024$218.14M+8.4%
Q1 FY2024Mar 31, 2024$217.89M-1.4%
Q4 FY2023Dec 31, 2023$222.51M-11.3%
Q3 FY2023Sep 30, 2023$229.20M-15.7%
Q2 FY2023Jun 30, 2023$201.22M-17.5%
Q1 FY2023Mar 31, 2023$220.88M-19.3%
Q4 FY2022Dec 31, 2022$250.95M-17.9%
Q3 FY2022Sep 30, 2022$271.95M-22.8%
Q2 FY2022Jun 30, 2022$243.97M-39.6%
Q1 FY2022Mar 31, 2022$273.72M-12.0%
Q4 FY2021Dec 31, 2021$305.71M-13.5%
Q3 FY2021Sep 30, 2021$352.39M-9.6%
Q2 FY2021Jun 30, 2021$404.25M-6.6%
Q1 FY2021Mar 31, 2021$310.93M-35.1%
Q4 FY2020Dec 31, 2020$353.56M-31.1%
Q3 FY2020Sep 30, 2020$390.02M-0.7%
Q2 FY2020Jun 30, 2020$432.72M+5.1%
Q1 FY2020Mar 31, 2020$478.94M+9.9%
Q4 FY2019Dec 31, 2019$512.78M+10.9%
Q3 FY2019Sep 30, 2019$392.96M-16.6%
Q2 FY2019Jun 30, 2019$411.67M-19.4%
Q1 FY2019Mar 31, 2019$435.79M+137.6%
Q4 FY2018Dec 31, 2018$462.18M+97.3%
Q3 FY2018Sep 30, 2018$470.90M+298.4%
Q2 FY2018Jun 30, 2018$510.56M+258.6%
Q1 FY2018Mar 31, 2018$183.38M-3.3%
Q4 FY2017Dec 31, 2017$234.31M+247.2%
Q3 FY2017Sep 30, 2017$118.20M+19.6%
Q2 FY2017Jun 30, 2017$142.37M–
Q1 FY2017Mar 31, 2017$189.56M–
Q4 FY2016Dec 31, 2016$67.48M–
Q3 FY2016Sep 30, 2016$98.81M–

More Heron Therapeutics figures

See a number that looks wrong?